휴비츠
Financials
Valuation Metrics
휴비츠's Market Cap is ₩757B. At end of 2025 it was ₩996B. Ranked #1433 of 2,436 in KR market (top 59%), #812 of 1,649 on KOSDAQ (top 49%), #54 of 96 in Health Care Equipment & Services (top 56%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 75.71B KRW | KR#1,433/2,436 Sec#54/96 |
| Revenue | 117.84B KRW | KR#1,315/2,436 Sec#25/96 |
| Net Income | -3.83B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 229.97B KRW | KR#1,192/2,436 Sec#30/96 |
| Net Assets | 114.37B KRW | KR#1,301/2,436 Sec#38/96 |
| Employees | 271 | KR#864/2,436 Sec#26/96 |
| Value | ||
| P/B | 0.66x | KR#1,095/2,436 Sec#20/96 |
| P/S | 0.64x | KR#1,095/2,436 Sec#13/96 |
| EV/EBITDA | 29.56x | KR#1,176/2,436 Sec#39/96 |
| FCF Yield | 7.28% | KR#737/2,436 Sec#15/96 |
| Profitability | ||
| ROE | -3.35% | KR#1,685/2,436 Sec#58/96 |
| ROA | -1.66% | KR#1,668/2,436 Sec#55/96 |
| Op. Margin | 4.16% | KR#1,030/2,436 Sec#44/96 |
| Revenue Growth | -0.69% | KR#1,482/2,436 Sec#65/96 |
| Earnings Growth | 40.67% | KR#620/2,436 Sec#25/96 |
| Financial Health | ||
| Debt Ratio | 201.06% | KR#1,722/2,436 Sec#80/96 |
| Total Debt | 75.17B KRW | KR#821/2,436 Sec#18/96 |
| FCF | 5.51B KRW | KR#876/2,436 Sec#24/96 |
| Cash | 5.90B KRW | KR#1,926/2,436 Sec#67/96 |
| Current Ratio | 1.09x | KR#1,723/2,436 Sec#79/96 |
| Net Debt/EBITDA | 14.12x | KR#1,361/2,436 Sec#47/96 |
| Dividend | ||
| Div. Yield | 3.60% | KR#509/2,436 Sec#5/96 |
| Div. Growth | 25.00% | KR#378/2,436 Sec#15/96 |
| Performance | ||
| 1Y Return | -24.10% | KR#1,405/2,436 Sec#42/96 |
| 1M Return | -4.00% | KR#1,300/2,436 Sec#58/96 |
| From 52W High | -31.02% | KR#436/2,436 Sec#13/96 |
| 1Y MDD | -34.79% | KR#340/2,436 Sec#8/96 |
| Trading | ||
| Volume | 20,608 shares | KR#1,833/2,436 Sec#75/96 |
| Foreign Own. | 3.93% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | -320 KRW | KR—/2,436 Sec—/96 |
| BPS | 10,194 KRW | KR#930/2,436 Sec#18/96 |
Company Info
Huvitz, established in 1999 and listed on the KOSDAQ market in 2003, plans to expand its implant business by acquiring shares in Osview in 2025. As a specialized ophthalmic medical device company, Huvitz produces South Korea's first optical coherence tomography diagnostic devices and auto refractometers, expanding its business across all optometric fields. The company invests over 10% of its annual revenue in research and development, with R&D personnel comprising 33% of its workforce, growing into a top-tier company in the ophthalmic diagnostic field. Huvitz is headquartered in Anyang-si, Gyeonggi-do.